RDTCF
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.01 | $656,372 | -$3M |
| 2025 Q2 | -0.01 | $672,921 | -$219,720 |
| 2025 Q1 | -0.01 | $782,741 | -$435,803 |
| 2025 Q4 | -0.01 | $668,577 | -$1,102 |
| 2024 Q3 | -0.01 | $501,689 | -$266,402 |
| 2024 Q2 | -0.01 | $515,916 | -$261,311 |
| 2024 Q1 | -0.01 | $398,994 | -$622,313 |
| 2024 Q4 | -0.02 | $192,652 | -$1M |